8-K Announcements
1Material company update
Sep 12, 2023·SEC
Tekla Life Sciences Investors(HQL)Earnings, Financials & Key Ratios
HQL•NYSE
$19.25
6.5× P/E·Price updated Jun 27, 2026
AboutTekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.Show more
- EBITDA$86M+282.9%
- Net Income$86M+282.9%
- EPS (Diluted)2.96+274.7%
- Gross Margin100%+115.5%
- EBITDA Margin99.08%+74.6%
- Operating Margin99.08%+844.2%
- Net Margin99.08%+74.6%
- ROE18.7%+234.5%
HQL Price & Volume
Tekla Life Sciences Investors (HQL) stock price & volume — 10-year historical chart
Loading chart...
Portfolio Volatility Masks Underlying Distribution Sustainability Risks
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Mixed
Profitability:Strained
Financial Position:Adequate
Cash Flow:Deteriorating
Primary Risk:Portfolio Valuation Volatility
"Tekla Life Sciences Investors operates as a closed-end fund with performance heavily tethered to the mark-to-market valuation of its concentrated, clinical-stage biotech holdings. While the fund has demonstrated a recovery in net income to $65.3M in 2026Q2, the lack of consistent operating cash flow and reliance on asset liquidations to fund distributions create significant long-term sustainability concerns. Investors should remain cautious as the fund's net asset value remains highly sensitive to sector-wide funding cycles and the inherent illiquidity of its underlying life sciences portfolio."
Verdict Logic
the fund's inability to generate positive free cash flow while maintaining an $18.2M dividend payment in 2026Q2 suggests a reliance on capital erosion to sustain distributions.
HQL Growth Metrics
Tekla Life Sciences Investors (HQL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years58.25%
5 Years104.07%
3 Years24.26%
TTM-
Profit CAGR
10 Years-0.42%
5 Years-
3 Years9.87%
TTM468.84%
EPS CAGR
10 Years-4.52%
5 Years-
3 Years3.63%
TTM412%
Return on Capital
10 Years3.19%
5 Years7.23%
3 Years-1.68%
Last Year18.68%
HQL Recent Earnings
Tekla Life Sciences Investors (HQL) EPS & revenue vs analyst estimates — last 4 quarters
Q3 2025Latest
Jun 24, 2025Metric
Actual
Est
EPS
$1.64
—
Rev
$18M
—
Q4 2024
Dec 9, 2024Metric
Actual
Est
EPS
$1.22
—
Rev
$2M
—
Q3 2024
Aug 6, 2024Metric
Actual
Est
EPS
$1.84
—
Rev
$2M
—
Q4 2023
Dec 11, 2023Metric
Actual
Est
EPS
$0.43
—
Rev
$30M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2025Latest | Jun 24, 2025 | $1.64 | $18M |
| Q4 2024 | Dec 9, 2024 | $1.22 | $2M |
| Q3 2024 | Aug 6, 2024 | $1.84 | $2M |
| Q4 2023 | Dec 11, 2023 | $0.43 | $30M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Tekla Life Sciences Investors (HQL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.25 | $585.35M | 6.50 | 119.34% | 99.08% | 18.7% | 5.69% | |
| $21.63 | $1.24B | 6.09 | 4.64% | 1145.63% | 24.26% | — | |
| $2.95 | $5.56M | -1.86 | 19.04% | -70.03% | -39.28% | — | |
| $1159.96 | $5.04B | 17.45 | 2.52% | 7.94% | 6.39% | — | |
| $59.00 | $11.35B | 32.78 | 12.87% | 8.29% | 4.41% | — | |
| $358.33 | $193.39B | 25.18 | 9.92% | 20.95% | 89.41% | — |
Compare HQL vs Peers
Tekla Life Sciences Investors (HQL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HQL SEC Filings & Documents
Tekla Life Sciences Investors (HQL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when HQL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HQL Frequently Asked Questions
Tekla Life Sciences Investors (HQL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Tekla Life Sciences Investors's revenue?
Tekla Life Sciences Investors (HQL) reported $107.5M in revenue for fiscal year 2025.
How fast is Tekla Life Sciences Investors growing?
Tekla Life Sciences Investors (HQL) grew revenue by 119.3% over the past year. This is strong growth.
Is HQL profitable?
Yes, Tekla Life Sciences Investors (HQL) is profitable, generating $139.5M in net income for fiscal year 2025 (99.1% net margin).
Dividend & Returns
Does HQL pay dividends?
Yes, Tekla Life Sciences Investors (HQL) pays a dividend with a yield of 5.69%. This makes it attractive for income-focused investors.
What is HQL's return on equity?
Tekla Life Sciences Investors (HQL) has a return on equity (ROE) of 18.7%. This is reasonable for most industries.
What is Tekla Life Sciences Investors's free cash flow?
Tekla Life Sciences Investors (HQL) had negative free cash flow of $3.5M in fiscal year 2025, likely due to heavy capital investments.